Related Experiment Video

Updated: Aug 14, 2026

5/6th Nephrectomy in Combination with High Salt Diet and Nitric Oxide Synthase Inhibition to Induce Chronic Kidney Disease in the Lewis Rat
08:50

5/6th Nephrectomy in Combination with High Salt Diet and Nitric Oxide Synthase Inhibition to Induce Chronic Kidney Disease in the Lewis Rat

Published on: July 3, 2013

Effect of FTY720 on chronic cyclosporine nephropathy in rats

Jin Young Kim1, Sun Woo Lim, Can Li

  • 1Xenotransplantation Center, Division of Nephrology, Department of Internal Medicine, The Catholic University of Korea, Seoul, Korea, and Department of Internal Medicine, The Affiliated Hospital, YanBian University Medical College, JiLin, China.

Transplantation
|November 30, 2005
PubMed
Abstract

Insights

FTY720, a lymphocyte inhibitor, significantly reduced kidney damage and inflammation in rats treated with cyclosporine A (CsA). This study demonstrates FTY720's protective effects against CsA-induced nephropathy.

Area of Science:

  • Nephrology
  • Immunology
  • Pharmacology

Background:

  • Long-term cyclosporine A (CsA) administration induces kidney tubulointerstitial inflammation and fibrosis.
  • Lymphocytes play a critical role in the pathogenesis of CsA nephropathy.

Purpose of the Study:

  • To investigate the therapeutic potential of FTY720, a lymphocyte-specific inhibitor, in a rat model of chronic CsA nephropathy.
  • To elucidate the role of lymphocytes in CsA-induced renal injury.

Main Methods:

  • Sprague-Dawley rats received daily CsA (7.5 mg/kg) or CsA plus FTY720 (0.125 mg/kg) for 4 weeks.
  • Renal function, histopathology, and expression of key injury mediators (osteopontin, TGF-beta1, betaig-h3, angiotensin II) were assessed.

Main Results:

  • FTY720 treatment markedly reduced T-lymphocyte and macrophage infiltration in rat kidneys.
  • Histopathological analysis revealed decreased interstitial fibrosis and improved renal function in FTY720-treated rats.
  • The expression of osteopontin, TGF-beta1, betaig-h3, and angiotensin II was significantly downregulated by FTY720.

Conclusions:

  • FTY720 effectively prevents CsA-induced renal dysfunction and histopathological damage.
  • Lymphocyte modulation with FTY720 offers a promising therapeutic strategy for CsA nephropathy.

Related Concept Videos

Renal Failure: Dose Adjustments01:11

Renal Failure: Dose Adjustments

In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant01:25

Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant

In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...
Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration01:28

Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration

Glomerular filtration rate (GFR) can be estimated from serum creatinine using the modification of diet in renal disease (MDRD) formula or the chronic kidney disease–epidemiology collaboration (CKD–EPI) equation. Both methods are widely used in clinical practice to assess kidney function and guide treatment decisions.The MDRD equation does not require weight or height measurements and is normalized to the body surface area of 1.73 m², considered the average adult surface area. This equation is...
Renal Drug Excretion: Tubular Secretion01:28

Renal Drug Excretion: Tubular Secretion

Active tubular secretion is a robust, energy-demanding process that utilizes carrier systems to transport drugs into renal tubules. The active renal secretion systems include the organic anion transporter (OAT) for weak acids and the organic cation transporter (OCT) for weak bases. Structurally similar drugs can compete for the same transporter, potentially leading to drug accumulation and toxicity. However, this principle can be exploited therapeutically. One example is probenecid (Probalan),...